Topic

Washington

A collection of 516 issues

Renewing Mepsevii (vestronidase alfa-vjbk) Approval with Blue Cross Blue Shield in Washington: 2025 Requirements & Timeline

Answer Box: Blue Cross Blue Shield requires annual prior authorization renewal for Mepsevii (vestronidase alfa-vjbk) in Washington, with updated documentation 60-90 days before expiration. Key requirements: confirmed MPS VII diagnosis via enzyme/genetic testing, current specialist prescription, evidence of ongoing clinical benefit, and proper dosing verification. Start renewal preparation 3
4 min read

How to Get Strimvelis Gene Therapy Covered by UnitedHealthcare in Washington: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Strimvelis Covered by UnitedHealthcare in Washington Strimvelis gene therapy for ADA-SCID requires prior authorization from UnitedHealthcare through OptumRx, with extensive documentation of genetic diagnosis (ICD-10 D81.31), failed standard therapies, and specialist support. Since Strimvelis isn't FDA-approved and is only available in Milan, Italy, you&
6 min read